Ritonavir

Overview
Catalog #	bs-75571c-10mg
Product Name	Ritonavir
Specifications
Storage Buffer	Solid
Storage Condition	Stable for 2 years after receipt when stored at -20°C.
Target
Product Information	CAS Number: 155213-67-5 Molecular formula: C37H48N6O5S2 Molecular weight: 720.9 Purity: >98% (HPLC) Appearance: White to off-white solid. Solubility: Soluble in DMSO (10mg/ml), DMF (10mg/ml) or EtOH. InChiKey: NCDNCNXCDXHOMX-XGKFQTDJSA-N SMILES: CC(C1=NC(CN(C(N[C@H](C(N[C@H](C[C@@H]([C@@H](NC(OCC2=CN=CS2)=O)CC3=CC=CC=C3)O)CC4=CC=CC=C4)=O)C(C)C)=O)C)=CS1)C
Description	HIV-1 and HIV-2 protease inhibitor. Glucose transporter 1 (GLUT1) and 4 (GLUT4) inhibitor. Inhibits transport of glucose across the plasma membranes of mammalian cells and consequently decreases glycolysis. Useful agent for immunometabolism research. Antitumor agent. Apoptosis inducer and cell proliferation inhibitor in GLUT1/GLUT4 overexpressed cancer cell lines. Tumor cells rely on elevated glucose consumption and metabolism for survival and proliferation. Glucose transporters mediating glucose entry are key proximal rate-limiting checkpoints. Among the fourteen SLC2A family members, GLUTs 1 and 4 are high-affinity glucose transporters. Inhibits 20S proteasome chymotrypsin-like activity. The proteinase inhibitor Kaletra, which is a mixture of the HIV-1 proteinase inhibitors lopinavir and ritonavir has been shown to be effective against SARS-CoV and MERS-CoV. Shown in a SARS-CoV-2 protease structure model study to potentially bind and inhibit the coronavirus endopeptidase C30 (CEP_C30) of SARS-CoV-2. An initial randomized trial study was not successful.